Haemonetics Corporation (HAE)
Haemonetics Statistics
Share Statistics
Haemonetics has 50.24M shares outstanding. The number of shares has increased by -1.11% in one year.
Shares Outstanding | 50.24M |
Shares Change (YoY) | -1.11% |
Shares Change (QoQ) | -1.86% |
Owned by Institutions (%) | 99.99% |
Shares Floating | 49.68M |
Failed to Deliver (FTD) Shares | 6.56K |
FTD / Avg. Volume | 0.7% |
Short Selling Information
The latest short interest is 4.96M, so 9.88% of the outstanding shares have been sold short.
Short Interest | 4.96M |
Short % of Shares Out | 9.88% |
Short % of Float | 9.99% |
Short Ratio (days to cover) | 10.74 |
Valuation Ratios
The PE ratio is 36.81 and the forward PE ratio is 13.06. Haemonetics's PEG ratio is 16.71.
PE Ratio | 36.81 |
Forward PE | 13.06 |
PS Ratio | 3.31 |
Forward PS | 2 |
PB Ratio | 4.51 |
P/FCF Ratio | 37.48 |
PEG Ratio | 16.71 |
Enterprise Valuation
Haemonetics Corporation has an Enterprise Value (EV) of 4.68B.
EV / Earnings | 39.84 |
EV / Sales | 3.58 |
EV / EBITDA | 17.64 |
EV / EBIT | 28.41 |
EV / FCF | 40.57 |
Financial Position
The company has a current ratio of 2.56, with a Debt / Equity ratio of 0.84.
Current Ratio | 2.56 |
Quick Ratio | 1.5 |
Debt / Equity | 0.84 |
Total Debt / Capitalization | 45.7 |
Cash Flow / Debt | 0.22 |
Interest Coverage | 12.67 |
Financial Efficiency
Return on equity (ROE) is 0.12% and return on capital (ROIC) is 7.22%.
Return on Equity (ROE) | 0.12% |
Return on Assets (ROA) | 0.05% |
Return on Capital (ROIC) | 7.22% |
Revenue Per Employee | $357,958.71 |
Profits Per Employee | $32,146.02 |
Employee Count | 3,657 |
Asset Turnover | 0.6 |
Inventory Turnover | 1.95 |
Taxes
Income Tax | 34.31M |
Effective Tax Rate | 0.23 |
Stock Price Statistics
The stock price has increased by -24.82% in the last 52 weeks. The beta is 0.43, so Haemonetics's price volatility has been higher than the market average.
Beta | 0.43 |
52-Week Price Change | -24.82% |
50-Day Moving Average | 66.5 |
200-Day Moving Average | 77.25 |
Relative Strength Index (RSI) | 44.03 |
Average Volume (20 Days) | 942.64K |
Income Statement
In the last 12 months, Haemonetics had revenue of 1.31B and earned 117.56M in profits. Earnings per share was 2.32.
Revenue | 1.31B |
Gross Profit | 691.55M |
Operating Income | 164.88M |
Net Income | 117.56M |
EBITDA | 265.58M |
EBIT | 164.88M |
Earnings Per Share (EPS) | 2.32 |
Balance Sheet
The company has 178.8M in cash and 807.79M in debt, giving a net cash position of -628.99M.
Cash & Cash Equivalents | 178.8M |
Total Debt | 807.79M |
Net Cash | -628.99M |
Retained Earnings | 360.46M |
Total Assets | 2.53B |
Working Capital | 752.63M |
Cash Flow
In the last 12 months, operating cash flow was 181.75M and capital expenditures -66.3M, giving a free cash flow of 115.45M.
Operating Cash Flow | 181.75M |
Capital Expenditures | -66.3M |
Free Cash Flow | 115.45M |
FCF Per Share | 2.28 |
Margins
Gross margin is 52.83%, with operating and profit margins of 12.6% and 8.98%.
Gross Margin | 52.83% |
Operating Margin | 12.6% |
Pretax Margin | 11.6% |
Profit Margin | 8.98% |
EBITDA Margin | 20.29% |
EBIT Margin | 12.6% |
FCF Margin | 8.82% |
Dividends & Yields
HAE does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | 3.62% |
FCF Yield | 3.58% |
Analyst Forecast
The average price target for HAE is $104, which is 62.1% higher than the current price. The consensus rating is "Buy".
Price Target | $104 |
Price Target Difference | 62.1% |
Analyst Consensus | Buy |
Analyst Count | 9 |
Stock Splits
The last stock split was on Dec 3, 2012. It was a forward split with a ratio of 2:1.
Last Split Date | Dec 3, 2012 |
Split Type | forward |
Split Ratio | 2:1 |
Scores
Altman Z-Score | 2.56 |
Piotroski F-Score | 6 |